Inside the Texas Heart Studio

Dr. Postalian is a cardiologist at The Texas Heart Institute, acting as a member of the teaching staff for the Institute's cardiovascular disease training programs and as an associate editor for The Texas Heart Institute Journal. Dr. Postalian specializes in coronary, peripheral vascular, and structural/valvular heart disease intervention. His specific clinical and research areas of interest include cardiovascular disease prevention – including complex lipid disorder management, state-of-the-art coronary intervention guided by intravascular imaging and flow assessment, next-day discharge transcatheter aortic valve replacement, and minimally invasive abdominal aortic aneurysm treatment. 

Professor of Medicine
Director, Center for the Diagnosis and Treatment of Pericardial Diseases
Director, Cardiovascular Imaging Research
Staff Cardiologist, Section of Cardiovascular Imaging
Robert and Suzanne Tomsich Department of Cardiovascular Medicine
Sydell and Arnold Miller Family Heart, Vascular & Thoracic Institute
Cleveland Clinic
Cleveland, Ohio

Professor, Department of Cardiac Sciences and Medicine
Section Chief, Cardiology Division
Libin Cardiovascular Institute of Alberta
Cummings School of Medicine
University of Calgary
Zone Head Cardiology
Calgary & Southeastern Alberta Region
Alberta Health Services
Calgary Alberta, Canada

Associate Professor of Medicine
Director, Electrophysiology Program
Department of Medicine, Division of Cardiology
University of Illinois College of Medicine
University of Illinois Chicago
University of Illinois Hospital
Jesse Brown VA Medical Center

Assistant Professor of Medicine
Division of Cardiology
Tufts University School of Medicine
Medical Director, Hypertrophic Cardiomyopathy Center
Lahey Hospital & Medical Center
Beth Israel Lahey Health
Burlington, Massachusetts

Overview:

Dr. Maron will provide an overview of the progress in the diagnosis, management and treatment strategies that have evolved over the last 60 years in hypertrophic cardiomyopathy (HCM). This will include the evolution of a mature risk stratification strategy and integration of implantable cardioverter defibrillators (ICDs) to HCM that have lowered sudden cardiac death event rates, as well as data supporting a low threshold for anticoagulation therapy in the setting of atrial fibrillation. In addition, we will discuss emergence of novel drug therapy with myosin inhibitors and their role in the current treatment strategy of symptomatic obstructive HCM patients.

Founder and CEO, Connected Cardiovascular Care Associates
Chief, Cardiovascular Strategic Planning and Development
Baylor Scott & White Health
Dallas, Texas

Yiannis S. Chatzizisis, MD, PhD is Professor of Cardiology, and Chief of the Cardiovascular Division at the Miller School of Medicine, University of Miami. He was trained in interventional cardiology and advanced non-invasive cardiovascular imaging at the Brigham and Women’s Hospital. His translational and clinical research is actively funded by the NIH, industry, and philanthropy (collectively $6 million over the last 6 years). He has authored more than 170 manuscripts published in Circulation, JACC, ATVB, Cardiovascular Research and Atherosclerosis among other journals.